Identification of a Wilms' tumor 1-derived immunogenic CD4+ T-cell epitope that is recognized in the context of common Caucasian HLA-DR haplotypes

Leukemia

Volumn 27, Issue 3, 2013, Pages 748-750

  Anguille, S ^a,b   Fujiki, F ^c   Smits, E L ^a,b   Oji, Y ^d   Lion, E ^b   Oka, Y ^d   Berneman, Z N ^a,b   Sugiyama, H ^d  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Department of Cancer Stem Cell Biology ^*  (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; EPITOPE; GAMMA INTERFERON; HLA DR ANTIGEN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; WILMS TUMOR 1 PROTEIN;

ALLELE; ANTIGEN EXPRESSION; CAUCASIAN; CD4+ T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; HAPLOTYPE; HELPER CELL; HUMAN; LETTER; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

CD4-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; EUROPEAN CONTINENTAL ANCESTRY GROUP; HAPLOTYPES; HLA-DR ANTIGENS; HUMANS; LEUKOCYTES, MONONUCLEAR; WT1 PROTEINS;

EID: 84875217332     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.248     Document Type: Letter

References (15)

1. Van Driessche A, Berneman ZN, Van Tendeloo VF. Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials. Oncologist 2012; 17: 250-259.
2. Anguille S, Van Tendeloo VF, Berneman ZN. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia 2012; e-pub ahead of print 6 July 2012; doi:10.1038/leu.2012.145.
3. Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004; 101: 13885-13890.
4. Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J et al. Leukemiaassociated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008; 111: 236-242.
5. Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW et al. A clinicaland immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009; 113: 6541-6548.
6. Van Tendeloo VF, Van de Velde A, Van Driessche A, Cools N, Anguille S, Ladell K et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci USA 2010; 107: 13824-13829.
7. Tsuboi A, Oka Y, Kyo T, Katayama Y, Elisseeva OA, Kawakami M et al. Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease. Leukemia 2012; 26: 1410-1413.
8. Anguille S, Lion E, Smits E, Berneman ZN, van Tendeloo VFI. Dendritic cell vaccine therapy for acute myeloid leukemia Questions and answers. Hum Vaccines 2011; 7: 579-584.
9. Fujiki F, Oka Y, Kawakatsu M, Tsuboi A, Nakajima H, Elisseeva OA et al. A WT1 protein-derived, naturally processed 16-mer peptide, WT1(332), is a promiscuous helper peptide for induction of WT1-specific Th1-type CD4(\+) T cells. Microbiol Immunol 2008; 52: 591-600.
10. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 2011; 39: D913-D919.
11. Williams F, Meenagh A, Single R, McNally M, Kelly P, Nelson MP et al. High resolution HLA-DRB1 identification of a caucasian population. Hum Immunol 2004; 65: 66-77.
12. Chattopadhyay PK, Yu J, Roederer M. A live-cell assay to detect antigen-specific CD4\+ T cells with diverse cytokine profiles. Nat Med 2005; 11: 1113-1117.
13. Bioley G, Dousset C, Yeh A, Dupont B, Bhardwaj N, Mears G et al. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4\+ T cell responses with a conserved T cell receptor repertoire. Clin Cancer Res 2009; 15: 4467-4474.
14. Faner R, James E, Huston L, Pujol-Borrel R, Kwok WW, Juan M. Reassessing the role of HLA-DRB3 T-cell responses: evidence for significant expression and complementary antigen presentation. Eur J Immunol 2010; 40: 91-102.
15. Fujiki F, Oka Y, Kawakatsu M, Tsuboi A, Tanaka-Harada Y, Hosen N et al. A clear correlation between WT1-specific Th response and clinical response in WT1 CTL epitope vaccination. Anticancer Res 2010; 30: 2247-2254.